

Accepted Manuscript

Accepted Manuscript (Uncorrected Proof)

Title: The Impact of Small Molecule Treatments on Viability of Astrocytes Derived from Human Epileptic Brain Tissues

Running title: Small Molecule on Viability of Astrocyte

Authors: Javad Momeni^{1,2,3,6}, Elham Hosseini^{1,2,3}, Maryam Khaleghi Ghadiri⁴, Fariborz Samini², Alireza Tabibkhoei⁵, Ali Gorji^{2,4,6,7}, Sajad Sahab Negah^{1,2,*}

1. *Department of Neuroscience, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.*
2. *Neuroscience Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.*
3. *Student research committee, Mashhad University of Medical Sciences, Mashhad, Iran.*
4. *Department of Neurosurgery, Münster University, Münster, Germany.*
5. *Department of Neurosurgery, Iran University of Medical Sciences, Tehran, Iran.*
6. *Shefa Neuroscience Research Center, Khatam Alanbia Hospital, Tehran, Iran.*
7. *Epilepsy Research Center, Münster University, Münster, Germany.*

***Corresponding Author:** Sajad Sahab Negah, Department of Neuroscience, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Email: Sahabnegahs@mums.ac.ir

To appear in: **Basic and Clinical Neuroscience**

Received date: 2024/12/14

Revised date: 2025/01/20

Accepted date: 2025/01/22

This is a “Just Accepted” manuscript, which has been examined by the peer-review process and has been accepted for publication. A “Just Accepted” manuscript is published online shortly after its acceptance, which is prior to technical editing and formatting and author proofing. *Basic and Clinical Neuroscience* provides “Just Accepted” as an optional and free service which allows authors to make their results available to the research community as soon as possible after acceptance. After a manuscript has been technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as a published article. Please note that technical editing may introduce minor changes to the manuscript text and/or graphics which may affect the content, and all legal disclaimers that apply to the journal pertain.

Please cite this article as:

Momeni, J., Hosseini, E., Khaleghi Ghadiri, M., Samini, F., Tabibkhooei, A., Gorji, A., et al. (In Press). The Impact of Small Molecule Treatments on Viability of Astrocytes Derived from Human Epileptic Brain Tissues. *Basic and Clinical Neuroscience*. Just Accepted publication Jul. 10, 2025. Doi: <http://dx.doi.org/10.32598/bcn.2025.5446.3>

DOI: <http://dx.doi.org/10.32598/bcn.2025.5446.3>

Abstract

Astrocyte dysfunction plays a crucial role in epileptogenesis by impacting neuronal excitability and synaptic transmission. The effect of small molecules on cellular functions depends on various factors, including the presence of specific target molecules within different cell types and tissues. This study investigates how specific small molecules impact the survival of astrocytes derived from various brain regions (the neocortex, hippocampus, or amygdala) of patients with medically refractory epilepsy. This study evaluated astrocyte responses to three distinct small molecules (valproate, forskolin, and GSK3 inhibitor/WNT activator CHIR99021), both individually and in combinations, to determine their differential effects on astrocyte survival. Our findings revealed that the effects of small molecules on astrocyte survival varied based on the brain tissue source and individual patient differences. Astrocytes from the amygdala of two patients showed heightened sensitivity to the small molecules, while astrocytes from the neocortex of one patient exhibited decreased viability following treatment with CHIR99021 and valproate. Moreover, astrocytes from the hippocampus exhibited a significant decrease in viability in one patient, whereas no significant changes were observed in other patients. Variability in astrocyte responses to small molecules, influenced by brain region and patient differences, may highlight their role in shaping diverse therapeutic outcomes in individuals. Further studies are required to clarify the factors involved in the different behaviors of astrocytes in response to small molecules in epilepsy.

Keywords: Small Molecule, Neuroglia, Seizure, Cell Proliferation, Treatment Outcomes

Introduction

Epilepsy is a neurological condition defined by repeated seizures caused by the synchronized, abnormal firing of groups of neurons. Glial cells are deeply involved in the genesis, development, and progression of epilepsy pathophysiology, mainly through their contribution to the synchronization of neural networks (Rosciszewski et al., 2019). These cells closely interact with neurons, regulate synaptic communication, and are involved in inflammatory processes and immune reactions (Diaz Verdugo et al., 2019; Heuser, Szokol, & Taubøll, 2014). Each type of glial cell possesses different properties that could be targeted to preserve neuronal health (Rasband, 2016). Several studies revealed significant phenotypical and functional heterogeneity of glial cells across various regions of the mammalian central nervous system (Tan, Yuan, & Tian, 2020). Emerging evidence suggests that glial cells undergo apoptosis and exhibit neuroinflammation in the epileptic focus, potentially contributing to epileptogenesis (Sokolova et al., 2022). Specifically, oligodendrocyte apoptosis has been linked to myelin damage in epilepsy (Sokolova et al., 2022). Furthermore, glial cells are involved in epileptogenesis through their interactions with neurons (Egaña-Huguet, Soria-Gómez, & Grandes, 2021). Astrocytes can sense and respond to neuronal activity, allowing them to regulate synaptic interactions (Tavassoli, Giahi, Janahmadi, & Hosseinmardi, 2022). Given the importance of astrocytes in epilepsy, modulating their function may offer therapeutic potential.

The longer duration of epilepsy is associated with decreased neuronal production and sustained astrogenesis (Ammothumkandy et al., 2022). Although immature neurons in mesial temporal lobe epilepsy (MTLE) remain inactive and are not present during local epileptiform activity, immature astroglia persists in all cases of MTLE. This astroglia, rather than new neurons, could be a potential target for regulating the hyperactivity of adult human neurons (Ammothumkandy

et al., 2022). For example, the endocannabinoid system in glial cells has been studied as a target for treating epilepsy in animal models (Egaña-Huguet et al., 2021). It has been suggested that glial cells could be considered valuable next-generation targets for designing anti-epileptic drugs, offering the potential to enhance outcomes for medically refractory epilepsy (Shen, Pristov, Nobili, & Nikolić, 2023).

Several studies have investigated small molecules' (SMs) ability to influence glial cell properties in epilepsy models. Recently, there have been reports indicating that SMs capable of binding to and activating K^+/Cl^- co-transporter (KCC2) have shown promise in reducing neuronal Cl^- accumulation and excitability. When KCC2 is selectively disabled in the hippocampus, it leads to the buildup of neuronal Cl^- and depolarizes GABAAR currents. These impairments in inhibition are associated with the beginning of unprovoked seizures, neuronal cell death, and the activation of reactive astrocytes. The activation of KCC2 by compound 350, a small molecule, has been found to both prevent the development of and halt ongoing benzodiazepine resistance (BDZ-RSE) status epilepticus in a mouse model of epilepsy. Furthermore, KCC2 activation has been shown to decrease neuronal cell death following BDZ-RSE (Jarvis et al., 2023).

Recently, several SMs have been investigated during glial pathogenesis in epilepsy. For instance, Valproate, an antiepileptic drug, has been shown to modulate glial cell function. Research has indicated that VPA can influence the development and differentiation of neural crest progenitors as well as hippocampal neural stem cells. Earlier research on VPA's effects on neural differentiation has mainly focused on how it influences transcription by inhibiting histone deacetylases (HDACs) (Almutawaa, Kang, Pan, & Niles, 2014; Hsieh, Nakashima, Kuwabara, Mejia, & Gage, 2004; Santos, Hubert, & Milthorpe, 2020; Yu et al., 2009). Other SMs, such as Forskolin and CHIR can influence cell signaling pathways (Han et al., 2023; B. Wang et al.,

2022; Yan, Gao, Cui, Zhang, & Zhou, 2016). Forskolin activates the enzyme adenylyl cyclase (AC) directly, leading to the production of cAMP from ATP and raising the levels of intracellular cAMP (Sapio et al., 2017). Prolonged cAMP activation in astrocytes increases glutamate transporter expression, while rapid cAMP spikes can reduce glutamate uptake by triggering the internalization of these transporters. Inhibiting AC or lowering intracellular cAMP can enhance glutamate uptake by preventing the internalization of GLT-1 and GLAST (Li et al., 2015). On the other hand, the Wnt/ β -catenin pathway is activated to prevent astrocytes from changing into different cell types by increasing the expression of Ngn2. After a stroke, a protein called Wnt2 is released from dying neurons, activating Wnt/ β -linked protein signaling in reactive astrocytes. This leads to the reversal of the specialized functions of astrocytes, which in turn supports the creation of new neurons in the cortex—indirectly activates the wnt pathway by inhibiting GSK-3 using CHIR99021, kenpaullone, and other small molecule compounds, leading to the expression of Ngn2 and encouraging astrocytes to transform into neurons (Cheng et al., 2015; L. Huang et al., 2024; Yin et al., 2019).

Mardones et al. (2024) investigate the Wnt signaling pathway in epileptogenesis using the activator Chir99021. They induced mesial temporal lobe epilepsy in wild-type and POMC-eGFP transgenic mice through intrahippocampal kainate injection, followed by 21 days of daily Chir99021 treatment starting 3 hours post-induction. The study revealed that IHK resulted in epilepsy after a 14-day latent period. Wnt activation significantly reduced seizure frequency and duration, with lasting effects. Additionally, dendritic structures were preserved, and object location memory improved post-treatment. These findings suggest that canonical Wnt activation may prevent epileptogenesis in the IHK mouse model, presenting a novel prevention strategy for epilepsy. (Mardones, Rostam, Nickerson, & Gupta, 2024). A study by Feng et al. (2024)

examined the effects of VPA on hippocampal astrogliosis in a rat model of TLE. Results showed that chronic VPA administration at 200 mg/kg significantly reduced astrogliosis and neuronal loss in the hippocampus after status epilepticus (SE) and improved cognitive impairments in KA-SE rats. Long-term administration at 400 mg/kg reduced astrogliosis at the middle stage post-SE but worsened cognitive impairments later. These findings suggest that VPA, at the right dosage, could reduce hippocampal astrogliosis and offer a potential new antiepileptic mechanism for long-term use (Feng et al., 2024). To date, no in vitro studies have examined the effects of small molecules on human astrocytes derived from epileptic patients. Therefore, our study sought to evaluate the impact of three small molecules—valproate, forskolin, and a GSK3 inhibitor/WNT activator (document_number_1; CHIR)—on the viability of astrocyte cells obtained from individuals with epilepsy. By investigating the effects of these compounds on astrocytes from epileptic patients, we seek to gain insights into their behavior across different brain regions in epilepsy.

Materials and Methods

Ethical statement:

The local Ethical Committee in Mashhad University of Medical Sciences (IR.MUMS.REC.1400.056) approved using resected patient tissue and the subsequent procedures conducted following the Declaration of Helsinki. Written informed consent was obtained from all subjects before each surgery.

Tissue preparation

Tissues from temporal lobe resections were collected from seven patients with drug-resistant temporal lobe epilepsy who underwent surgery at Khatam Alanbia Hospital in Tehran and Imam Reza Hospital in Mashhad, Iran.

Primary Cell Culture

After the neurosurgeon resected the tissue in the operating room, the tissue was transferred to the cell culture laboratory in a conical tube containing cold PBS (Gibco, Germany) and Pen/Strep (Sigma, Germany) 10% solution. In the laboratory, the tissue was transferred to a petri dish. Then, the necrotic tissues, blood vessels, and white matter were separated using a scalpel and forceps. Next, the mechanical digestion was performed for 3 minutes. The tissue was overlaid with cold PBS. Then, the tissue was transferred to a falcon and centrifuged at 1500 rpm. After removing the supernatant, trypsin (Gibco, Germany) was added to the tissue (at twice the amount of the tissue) for 5 minutes at 37°C. To neutralize the medium, twice the amount of culture medium containing FBS (Gibco, Germany) was added to a falcon and centrifuged at 1200 rpm for 3 minutes. After removing the supernatant, we added a medium and passed it through a cell strainer 70 µm. Finally, cells were counted and transferred to the flask.

Following a 70% confluency, we isolated astrocytes using the MD-astrocyte model. This model is predicated on the death of neurons, which triggers the rapid proliferation of astrocytes and oligodendrocytes in culture. It also involves the selective detachment of the upper oligodendrocytes, which occurs when the cultures are subjected to shear forces generated by shaking (Creighton, Ruffins, & Lorenzo, 2019; S. Liddelow, 2017; Schildge, Bohrer, Beck, & Schachtrup, 2013).

Cell counting and plating

The medium for expansion contained Dulbecco's modified Eagle's medium/F12 (Invitrogen, Germany) with the addition of 0.5% N2 supplement (Invitrogen, Germany), 1% B27 supplement (Invitrogen, Germany), 2 µg/ml heparin (Sigma, Germany), 1% penicillin/streptomycin, 1% glutamine (Invitrogen, Germany), 20 ng/ml essential fibroblast growth factor (bFGF; Millipore, Germany), and 20 ng/ml epidermal growth factor (EGF; (Sigma, Germany). The medium was changed every three days, and cells were transferred every seven days and re-cultured in a fresh growth medium. The cell cultures were kept in an incubator (Mettler, Germany) at 37 °C with 95% air and 5% CO₂. Astrocyte cells were cultured separately and expanded to the third passage under similar culture conditions.

SMs treatment

In our research, we utilized three distinct SMs: CHIR99021 (CHIR, Sigma, SML1046), Valproic Acid (VPA, Sigma, P4543), and Forskolin (FOR, Sigma, F3917). Additionally, BDNF (Sigma, B3795) was employed as a growth factor in certain groups. The Astrocyte cells were exposed to BDNF at 50 ng/ml, CHIR at 3µM, VPA at 1mM, and FORS at 100 µM. Cell viability was then measured at 48 and 72 hours post-treatment. Combining these SMs, we structured 12 groups, detailed in Table 1. In each group, we used neural basal medium containing B27: 1%, L-Glu: 1%, Pen/Strep: 1%, and N2: 0.5%.

Table 1

Immunocytochemistry Assay

We performed immunocytochemistry to characterize cells. Initially, we discarded the culture medium and rinsed the cells with PBS. Next, we treated the cells with 4% paraformaldehyde for

30 minutes to fix them. Following that, we permeabilized the cells using a Triton X-100 solution and applied normal goat serum and BSA as blocking agents. We then applied primary antibodies, such as GFAP (Sigma, Germany) at a 1:200 dilution, Vimentin (Santa Cruz, Germany) at a 1:100 dilution, and Fibronectin (Merk, Germany) at a 1:100 dilution, as markers for astrocytic cells at 4°C. After this, we applied secondary antibodies, including goat anti-mouse FITC (Abcam, UK), for 1.5 hours at room temperature. We used PI to stain cell nuclei and incubated secondary antibodies alone to identify negative controls. Finally, we examined the data using fluorescent microscopy (Olympus, Germany). The tissue derived from patient number 1 for the amygdala, number 7 for the neocortex, and number 4 for the hippocampus was used for cell characterization.

Cell viability Assay

Cell viability was determined using an MTT assay (Atocel, Austria). Astrocyte cells (1×10^4 /well) were incubated in 96-well culture dishes overnight. Subsequently, the cells were exposed to various SMs for 48 or 72 hours. After the treatment, ten μL of MTT solution in PBS (5 mg/ml) was applied to each well to achieve a final concentration of 0.05%. Following a 3-hour incubation, the supernatant was discarded, and 100 μL of dimethyl sulfoxide (Sigma, Germany) was introduced to dissolve the formazan crystals. The microplates were gently agitated without light for 60 minutes, and the absorbance was gauged between 570 and 630 nm using a Stat FAX303 plate reader (Rasti et al., 2024).

Statistical analysis

The current study presented data as means \pm standard deviation (SD), utilizing GraphPad Prism for analysis (version 5). Statistical variations among the groups were determined through one-

way analysis of variance (ANOVA). A threshold of $P < 0.05$ (*) was used to signify the levels of statistical significance.

Results

Demographic data

This study was conducted on brain tissue from seven individuals with medically intractable epilepsy who had undergone surgery. Four participants were male, with an average age of 35.37 years (SD = 8.87), ranging from 26 to 44 years. The duration of their seizures varied between 9 and 46 years. All patients had been using two or three medications before surgery. Neuropsychiatric symptoms, including cognitive impairments and depression, were observed in four patients (Table 2).

Table 2

Isolation and Expansion of human astrocyte cells

Human astrocyte cells were isolated and cultured from resected mesial temporal lobe tissues during epilepsy surgery. Following the primary culture, the cells achieved 80% confluence within ten days (Fig. 1). The astrocytes exhibit diverse shapes and intricate structures. The main processes, called "branches," originate from the soma, with their precise number being diverse. The neocortex cells have fewer branches than those in the amygdala and hippocampus.

Fig. 1

Immunocytochemistry Assay

We analyzed the expression levels of GFAP, vimentin, and Fibronectin markers. Our findings revealed a negative expression of the GFAP marker and a positive expression of Vimentin and

fibronectin (Fig. 2). The findings are consistent with previous studies (Macikova, Perzelova, Mraz, Bizik, & Steno, 2009; Perzelova et al., 2007), which shows that astrocytes derived from human brain tissues predominantly express vimentin (100%) and fibronectin (95%), with only 0.1% testing positive for GFAP. Building on these findings, we effectively isolated and purified astrocytes for further analysis.

Fig. 2

Cell viability assay

The viability of astrocytes derived from epileptic tissue was evaluated after treatment with SMs and compared to cells that were not treated. Our findings indicate that specific SMs can inhibit the viability of astrocytes when used alone or in combination with others, depending on the cell source and individual patients. For instance, two patients' astrocytes from the amygdala exhibited more robust responses to SMs (Fig. 3 A, B). In contrast, astrocytes from the neocortex showed reduced viability in only one group (CHIR+VPA) (Fig. 3 E, F). Interestingly, astrocytes from the hippocampus exhibited a significant decrease in viability for one patient across all groups, while another showed no substantial changes (Fig. 3 C, D).

Fig. 3

Discussion

Astroglial cells make up around 30% of all cells in the adult mammalian CNS, making them the most prevalent cell type (S. A. Liddel & Barres, 2017). These cells share early progenitor cells with neurons. They are highly likely to be converted into neurons in neurological disorders, where there is neuronal loss or a high number of astrocytes due to uncontrolled proliferation. Thus, inhibiting astrocyte proliferation, mainly astrogliosis, occurs in epilepsy and creates a

chaotic environment; targeting the proliferation and viability of astrocytes could be a novel approach to managing MTLE (Chandrasekaran, Avci, Leist, Kobolák, & Dinnyés, 2016; Westergard & Rothstein, 2020). Our study demonstrates that specific SMs can reduce the viability of astrocytes in some epileptic patients. To arrive at a valid conclusion, we conducted viability assays on astrocytes isolated from different tissues (amygdala, hippocampus, and cortex) obtained from intractable epileptic patients individually. Notably, tissue heterogeneity, brain localization, and the timing of epilepsy onset and seizure duration may influence the cellular response to our intervention (Wong, 2019). However, the results of two studies have indicated that the differentiation of astrocytes derived from human fetal brain tissue and cell lines was taken into neurons (exposed to TTNPB, SB431542, LDN193189, Thiazovivin, CHIR99021, DAPT, VPA, SAG, pumorphamine) and oligodendrocytes (exposed to CHIR99021, Forskolin, Repsox, LDN, VPA and Thiazovivin), respectively, when exposed to SMs (Sharifi-Kelishadi, Zare, Fathollahi, & Javan, 2024; Zhang et al., 2015). This means SMs can regulate astrocyte molecular mechanisms. The difference between this study and our findings was that we used several tissues, while these two studies assessed their response on one cell type or cell lines. The heterogeneity of cells was evident in our study; this might affect the response to SMs. Another difference was that the outcome of our study was viability for a maximum of 72 hours, while those studies evaluated differentiation during 10 days. Additionally, we just used three SMs, while they used 9 SMs for neuronal differentiation and 6 SMs for oligodendrogenesis.

Recent studies indicate that Wnt/ β -catenin signaling is involved in neurogenesis and neuronal reorganization during epileptogenesis (C. Huang, Fu, Zhou, & Li, 2015; Moncion, West, & Metcalf, 2024; Qu et al., 2017). Rawat et al. (2023) used a lithium-pilocarpine model of status epilepsy (SE) and found that this signaling pathway was inactive during the acute phase but

activated in the chronic stage. This activation may increase neuronal count, synaptic density, astrogliosis, and apoptosis in chronic epilepsy. The findings suggest that targeting GSK-3 β could be beneficial in the acute stage, while addressing the chronic stage may require targeting β -catenin and disheveled proteins (Rawat, Gautam, Sandhu, Bhatia, & Saha, 2023). Recent studies show that valproic acid (VPA) exerts anti-epileptic effects by modulating the excitatory/inhibitory (E/I) balance through astrocytes (Takeda et al., 2021). As a histone deacetylase (HDAC) inhibitor, VPA influences gene expression in astrocytes, affecting mRNA levels of cell adhesion molecules and extracellular matrix proteins in a time- and concentration-dependent manner. VPA also increases levels of excitatory (PSD-95) and inhibitory (Gephyrin) proteins in mixed cultures, indicating its role in regulating E/I balance through astrocytic mechanisms, which warrant further research on astroglial contributions to synapse formation (C. C. Wang et al., 2012). We found that the combination of CHIR and VPA reduces astrocyte viability, suggesting that these small molecules may inhibit astrogliosis in the context of epilepsy.

Consistent with our results, it has been reported that SMs could inhibit neuroinflammation by inhibiting proinflammatory cytokines. In this regard, we found that SMs could inhibit the survival of astrocytes, which is a primary source of proinflammatory production (Dey, Kang, Qiu, Du, & Jiang, 2016).

We have found that specific drug/small molecule screenings are achievable using cells obtained from epileptic tissue. This discovery is a significant step forward in personalized medicine. Our findings demonstrate that patient responses vary, and intriguingly, we observed varied reactions in terms of cell localization. The complexity of epilepsy is attributed to various mechanisms, such as the imbalance between inhibitory and excitatory neurotransmission, heightened

inflammation, specific brain region neuronal damage, and irregularities in neuronal and cortical development. These mechanisms result in varied responses to pharmacological interventions (do Canto et al., 2021). For example, following the analysis of 57 TLE samples along with one control through histochemistry and electron microscopy, researchers identified considerable variation among the samples. Some patients experienced pronounced segmental loss in the hippocampus, while others showed moderate neuronal loss in the hippocampus, with a few not exhibiting any pathological changes whatsoever (Kunz et al., 2000).

Another crucial mechanism in epilepsy, recently highlighted, is biophysical heterogeneity. This phenomenon significantly reduces neuronal diversity within seizure-generating regions (Rich, Moradi Chameh, Lefebvre, & Valiante, 2022). Within this context, using SMs could boost neuronal diversity by stimulating the creation of new neurons in regions prone to seizures. In particular, compounds like retinoic acid, Notch inhibitors, WNT activators, and DNMT inhibitors can prompt the transformation of neural cells from human fibroblasts by triggering autophagy and reducing ROS production (Rujanapun et al., 2019). Thus, SMs can inhibit astrogliosis while conversely having the potential to enhance neuronal production. This presents a novel approach in epilepsy for modifying cellular architecture and addressing neuronal heterogeneity. The primary limitation of this investigation was the limited sample size (n=7). Future research should aim to involve a larger cohort of participants to enhance the robustness and generalizability of the findings.

Conclusion

In summary, targeting the proliferation and viability of astrocyte cells represents a promising approach to managing MTLE. Our study, which involved viability assays on cells from different tissues obtained from intractable epileptic patients, highlights the importance of considering

tissue heterogeneity, brain localization, and timing of epilepsy onset. Notably, patient responses vary, and the complexity of epilepsy involves multiple mechanisms. Finally, to better understand the effects of SMs, the following recommendations are suggested: i) Conduct large-scale studies to analyze patient responses to different SMs, considering factors such as genetic variations, comorbidities, and lifestyle. ii) Investigate the synergistic effects of combining SMs with other therapeutic approaches, such as antiepileptic drugs, immunomodulators, or stem cell therapies. iii) Explore specific SMs that can selectively modulate glial cell viability without affecting neuronal health.

Acknowledgments

We thank the Imam Reza Hospital and Khatam Alanbia Hospital patients for cooperating with this manuscript.

Funding

This study was financially supported by the Council for Development of Stem Cell Sciences and Technologies, Tehran, Iran, under grant number (104552) and supported by Mashhad University of Medical Sciences, Mashhad, Iran (991796).

Potential Conflict of Interest

All authors declared that there is no conflict of interest.

References:

- Almutawaa, W., Kang, N. H., Pan, Y., & Niles, L. P. (2014). Induction of Neurotrophic and Differentiation Factors in Neural Stem Cells by Valproic Acid. *115*(2), 216-221. doi:<https://doi.org/10.1111/bcpt.12201>
- Ammothumkandy, A., Ravina, K., Wolseley, V., Tartt, A. N., Yu, P. N., Corona, L., . . . Bonaguidi, M. A. (2022). Altered adult neurogenesis and gliogenesis in patients with mesial temporal lobe epilepsy. *Nat Neurosci*, *25*(4), 493-503. doi:10.1038/s41593-022-01044-2
- Chandrasekaran, A., Avci, H. X., Leist, M., Kobolák, J., & Dinnyés, A. (2016). Astrocyte Differentiation of Human Pluripotent Stem Cells: New Tools for Neurological Disorder Research. *Front Cell Neurosci*, *10*, 215. doi:10.3389/fncel.2016.00215
- Cheng, L., Gao, L., Guan, W., Mao, J., Hu, W., Qiu, B., . . . Pei, G. (2015). Direct conversion of astrocytes into neuronal cells by drug cocktail. *Cell Res*, *25*(11), 1269-1272. doi:10.1038/cr.2015.120
- Creighton, B. A., Ruffins, T. W., & Lorenzo, D. N. (2019). Visualizing and Analyzing Intracellular Transport of Organelles and Other Cargos in Astrocytes. *J Vis Exp*(150). doi:10.3791/60230
- Dey, A., Kang, X., Qiu, J., Du, Y., & Jiang, J. (2016). Anti-Inflammatory Small Molecules To Treat Seizures and Epilepsy: From Bench to Bedside. *Trends Pharmacol Sci*, *37*(6), 463-484. doi:10.1016/j.tips.2016.03.001
- Diaz Verdugo, C., Myren-Svelstad, S., Aydin, E., Van Hoeymissen, E., Deneubourg, C., Vanderhaeghe, S., . . . Yaksi, E. (2019). Glia-neuron interactions underlie state transitions to generalized seizures. *Nat Commun*, *10*(1), 3830. doi:10.1038/s41467-019-11739-z
- do Canto, A. M., Donatti, A., Geraldis, J. C., Godoi, A. B., da Rosa, D. C., & Lopes-Cendes, I. (2021). Neuroproteomics in Epilepsy: What Do We Know so Far? *Frontiers in Molecular Neuroscience*, *13*. doi:10.3389/fnmol.2020.604158
- Egaña-Huguet, J., Soria-Gómez, E., & Grandes, P. (2021). The Endocannabinoid System in Glial Cells and Their Profitable Interactions to Treat Epilepsy: Evidence from Animal Models. *International Journal of Molecular Sciences*, *22*(24), 13231.
- Feng, H., Luo, J., Li, Z., Zhao, Y., Liu, Y., & Zhu, H. (2024). Valproic acid attenuates the severity of astrogliosis in the hippocampus of animal models of temporal lobe epilepsy. *IBRO Neuroscience Reports*, *17*, 471-479. doi:10.1016/j.ibneur.2024.11.003
- Han, Y., He, Y., Jin, X., Xie, J., Yu, P., Gao, G., . . . Chang, Y. Z. (2023). CHIR99021 Maintenance of the Cell Stemness by Regulating Cellular Iron Metabolism. *Antioxidants (Basel)*, *12*(2). doi:10.3390/antiox12020377
- Heuser, K., Szokol, K., & Taubøll, E. (2014). The role of glial cells in epilepsy. *Tidsskr Nor Laegeforen*, *134*(1), 37-41. doi:10.4045/tidsskr.12.1344
- Hsieh, J., Nakashima, K., Kuwabara, T., Mejia, E., & Gage, F. H. (2004). Histone deacetylase inhibition-mediated neuronal differentiation of multipotent adult neural progenitor cells. *Proc Natl Acad Sci U S A*, *101*(47), 16659-16664. doi:10.1073/pnas.0407643101
- Huang, C., Fu, X.-H., Zhou, D., & Li, J.-M. (2015). The Role of Wnt/ β -Catenin Signaling Pathway in Disrupted Hippocampal Neurogenesis of Temporal Lobe Epilepsy: A Potential Therapeutic Target? *Neurochem Res*, *40*(7), 1319-1332. doi:10.1007/s11064-015-1614-1
- Huang, L., Lai, X., Liang, X., Chen, J., Yang, Y., Xu, W., . . . Chen, L. (2024). A promise for neuronal repair: reprogramming astrocytes into neurons in vivo. *Biosci Rep*, *44*(1). doi:10.1042/bsr20231717
- Jarvis, R., Josephine Ng, S. F., Nathanson, A. J., Cardarelli, R. A., Abiraman, K., Wade, F., . . . Moss, S. J. (2023). Direct activation of KCC2 arrests benzodiazepine refractory status epilepticus and limits the subsequent neuronal injury in mice. *Cell Rep Med*, *4*(3), 100957. doi:10.1016/j.xcrm.2023.100957

- Kunz, W. S., Kudin, A. P., Vielhaber, S., Blümcke, I., Zuschmitter, W., Schramm, J., . . . Elger, C. E. (2000). Mitochondrial complex I deficiency in the epileptic focus of patients with temporal lobe epilepsy. *Ann Neurol*, *48*(5), 766-773.
- Li, D., Héroult, K., Zylbersztejn, K., Lauterbach, M. A., Guillon, M., Oheim, M., & Ropert, N. (2015). Astrocyte VAMP3 vesicles undergo Ca²⁺-independent cycling and modulate glutamate transporter trafficking. *J Physiol*, *593*(13), 2807-2832. doi:10.1113/jp270362
- Liddel, S. (2017). Purification and Culture Methods for Astrocytes. *Front Cell Neurosci*. Retrieved from <https://www.sfn.org/-/media/Project/Neuronline/PDFs/2018/Purification-and-Culture-Methods-for-Astrocytes.pdf>
- Liddel, S. A., & Barres, B. A. (2017). Reactive Astrocytes: Production, Function, and Therapeutic Potential. *Immunity*, *46*(6), 957-967. doi:<https://doi.org/10.1016/j.immuni.2017.06.006>
- Macikova, I., Perzelova, A., Mraz, P., Bizik, I., & Steno, J. J. B. (2009). GFAP-positive astrocytes are rare or absent in primary adult human brain tissue cultures. *64*(4), 833-839.
- Mardones, M. D., Rostam, K. D., Nickerson, M. C., & Gupta, K. (2024). Canonical Wnt activator Chir99021 prevents epileptogenesis in the intrahippocampal kainate mouse model of temporal lobe epilepsy. *Exp Neurol*, *376*, 114767. doi:10.1016/j.expneurol.2024.114767
- Moncion, C., West, P. J., & Metcalf, C. S. (2024). Wnt Signaling: The Next Step on the Road to Anti-Epileptogenic Therapies? *Epilepsy Currents*, *24*(5), 355-357. doi:10.1177/15357597241280467
- Perzelova, A., Macikova, I., Tardy, M., Mraz, P., Bizik, I., & Steno, J. J. B. (2007). Subpopulation of nestin positive glial precursor cells occur in primary adult human brain cultures. *62*(5), 633-640.
- Qu, Z., Su, F., Qi, X., Sun, J., Wang, H., Qiao, Z., . . . Zhu, Y. (2017). Wnt/ β -catenin signalling pathway mediated aberrant hippocampal neurogenesis in kainic acid-induced epilepsy. *35*(7), 472-476. doi:<https://doi.org/10.1002/cbf.3306>
- Rasband, M. N. (2016). Glial Contributions to Neural Function and Disease. *Mol Cell Proteomics*, *15*(2), 355-361. doi:10.1074/mcp.R115.053744
- Rasti, M., Parniaei, A. H., Dehghani, L., Nasr Esfahani, S., Mirhendi, H., Yazdani, V., & Azimian Zavareh, V. (2024). Enhancing the wound healing process through local injection of exosomes derived from blood serum: An in vitro and in vivo assessment. *Regen Ther*, *26*, 281-289. doi:10.1016/j.reth.2024.06.004
- Rawat, K., Gautam, V., Sandhu, A., Bhatia, A., & Saha, L. (2023). Differential Regulation of Wnt/ β -catenin Signaling in Acute and Chronic Epilepsy in Repeated Low Dose Lithium-Pilocarpine Rat Model of Status Epilepticus. *Neuroscience*, *535*, 36-49. doi:10.1016/j.neuroscience.2023.10.019
- Rich, S., Moradi Chameh, H., Lefebvre, J., & Valiante, T. A. (2022). Loss of neuronal heterogeneity in epileptogenic human tissue impairs network resilience to sudden changes in synchrony. *Cell Rep*, *39*(8), 110863. doi:10.1016/j.celrep.2022.110863
- Rosciszewski, G., Cadena, V., Auzmendi, J., Cieri, M. B., Lukin, J., Rossi, A. R., . . . Ramos, A. J. (2019). Detrimental Effects of HMGB-1 Require Microglial-Astroglial Interaction: Implications for the Status Epilepticus-Induced Neuroinflammation. *Front Cell Neurosci*, *13*, 380. doi:10.3389/fncel.2019.00380
- Rujanapun, N., Heebkaew, N., Promjantuek, W., Sotthibundhu, A., Kunhorm, P., Chaicharoenaudomrung, N., & Noisa, P. (2019). Small molecules re-establish neural cell fate of human fibroblasts via autophagy activation. *In Vitro Cell Dev Biol Anim*, *55*(8), 622-632. doi:10.1007/s11626-019-00381-0
- Santos, J., Hubert, T., & Milthorpe, B. K. (2020). Valproic Acid Promotes Early Neural Differentiation in Adult Mesenchymal Stem Cells Through Protein Signalling Pathways. *Cells*, *9*(3). doi:10.3390/cells9030619

- Sapio, L., Gallo, M., Illiano, M., Chiosi, E., Naviglio, D., Spina, A., & Naviglio, S. (2017). The Natural cAMP Elevating Compound Forskolin in Cancer Therapy: Is It Time? *J Cell Physiol*, 232(5), 922-927. doi:10.1002/jcp.25650
- Schildge, S., Bohrer, C., Beck, K., & Schachtrup, C. (2013). Isolation and culture of mouse cortical astrocytes. *J Vis Exp*(71). doi:10.3791/50079
- Sharifi-Kelishadi, M., Zare, L., Fathollahi, Y., & Javan, M. (2024). Conversion of Astrocyte Cell Lines to Oligodendrocyte Progenitor Cells Using Small Molecules and Transplantation to Animal Model of Multiple Sclerosis. *J Mol Neurosci*, 74(2), 40. doi:10.1007/s12031-024-02206-6
- Shen, W., Pristov, J. B., Nobili, P., & Nikolić, L. (2023). Can glial cells save neurons in epilepsy? *Neural Regen Res*, 18(7), 1417-1422. doi:10.4103/1673-5374.360281
- Sokolova, T. V., Zabrodskaya, Y. M., Litovchenko, A. V., Paramonova, N. M., Kasumov, V. R., Kravtsova, S. V., . . . Bazhanova, E. D. (2022). Relationship between Neuroglial Apoptosis and Neuroinflammation in the Epileptic Focus of the Brain and in the Blood of Patients with Drug-Resistant Epilepsy. *Int J Mol Sci*, 23(20). doi:10.3390/ijms232012561
- Takeda, K., Watanabe, T., Oyabu, K., Tsukamoto, S., Oba, Y., Nakano, T., . . . Iwasaki, K. (2021). Valproic acid-exposed astrocytes impair inhibitory synapse formation and function. *Scientific Reports*, 11(1), 23. doi:10.1038/s41598-020-79520-7
- Tan, Y. L., Yuan, Y., & Tian, L. (2020). Microglial regional heterogeneity and its role in the brain. *Mol Psychiatry*, 25(2), 351-367. doi:10.1038/s41380-019-0609-8
- Tavassoli, Z., Giahi, M., Janahmadi, M., & Hosseinmardi, N. (2022). Glial cells inhibition affects the incidence of metaplasticity in the hippocampus of Pentylentetrazole-induced kindled rats. *Epilepsy Behav*, 135, 108907. doi:10.1016/j.yebeh.2022.108907
- Wang, B., Khan, S., Wang, P., Wang, X., Liu, Y., Chen, J., & Tu, X. (2022). A Highly Selective GSK-3 β Inhibitor CHIR99021 Promotes Osteogenesis by Activating Canonical and Autophagy-Mediated Wnt Signaling. *Front Endocrinol (Lausanne)*, 13, 926622. doi:10.3389/fendo.2022.926622
- Wang, C. C., Chen, P. S., Hsu, C. W., Wu, S. J., Lin, C. T., & Gean, P. W. (2012). Valproic acid mediates the synaptic excitatory/inhibitory balance through astrocytes--a preliminary study. *Prog Neuropsychopharmacol Biol Psychiatry*, 37(1), 111-120. doi:10.1016/j.pnpbp.2012.01.017
- Westergard, T., & Rothstein, J. D. (2020). Astrocyte Diversity: Current Insights and Future Directions. *Neurochem Res*, 45(6), 1298-1305. doi:10.1007/s11064-020-02959-7
- Wong, M. (2019). The role of glia in epilepsy, intellectual disability, and other neurodevelopmental disorders in tuberous sclerosis complex. *Journal of Neurodevelopmental Disorders*, 11(1), 30. doi:10.1186/s11689-019-9289-6
- Yan, K., Gao, L. N., Cui, Y. L., Zhang, Y., & Zhou, X. (2016). The cyclic AMP signaling pathway: Exploring targets for successful drug discovery (Review). *Mol Med Rep*, 13(5), 3715-3723. doi:10.3892/mmr.2016.5005
- Yin, J. C., Zhang, L., Ma, N. X., Wang, Y., Lee, G., Hou, X. Y., . . . Chen, G. (2019). Chemical Conversion of Human Fetal Astrocytes into Neurons through Modulation of Multiple Signaling Pathways. *Stem Cell Reports*, 12(3), 488-501. doi:10.1016/j.stemcr.2019.01.003
- Yu, I. T., Park, J. Y., Kim, S. H., Lee, J. S., Kim, Y. S., & Son, H. (2009). Valproic acid promotes neuronal differentiation by induction of proneural factors in association with H4 acetylation. *Neuropharmacology*, 56(2), 473-480. doi:10.1016/j.neuropharm.2008.09.019
- Zhang, L., Yin, J. C., Yeh, H., Ma, N. X., Lee, G., Chen, X. A., . . . Chen, G. (2015). Small Molecules Efficiently Reprogram Human Astroglial Cells into Functional Neurons. *Cell Stem Cell*, 17(6), 735-747. doi:10.1016/j.stem.2015.09.012

Tables/Figure Legends

Table 1: Different groups of SMs

Table 2: Demographic and clinical data of epileptic surgery patients

Fig. 1: Primary cultures of astrocytes derived from patients with intractable epilepsy, derived from the amygdala, neocortex, and hippocampus.

Fig. 2: Expression of vimentin and fibronectin in astrocytes derived from human epileptic brain tissues. Cells stained for markers are green, and nuclei stained with propidium iodide (PI) are red.

Fig. 3: Treatment of different SMs on astrocyte cell survival.

Accepted Manuscript (Uncorrected Proof)

Table 1: Different groups of SMs

Groups name	Description	Additive
GF -	Neural basal medium*	-
BDNF	+	BDNF (50ng/ml)
CHIR	+	CHIR (3 μ M)
VPA	+	VPA (1mM)
FOR	+	FOR (100 μ M)
CHIR+VPA	+	CHIR (3 μ M) +VPA (1mM)
CHIR+FOR	+	CHIR (3 μ M) +FOR (100 μ M)
VPA+FOR	+	VPA (1mM) +FOR (100 μ M)
BDNF+VPA	+	BDNF (50ng/ml) +VPA (1mM)
BDNF+FOR	+	BDNF (50ng/ml) +FOR (100 μ M)
Cocktail	+	CHIR (3 μ M) +VPA (1mM) +FOR (100 μ M)
Cocktail +BDNF	+	CHIR (3 μ M) +VPA (1mM) +FOR (100 μ M) +BDNF (50ng/ml)

* Neural basal medium containing B27: 1%, L-Glu: 1%, Pen/Strep: 1%, N2: 0.5%

Table 2: Demographic and clinical data of epileptic surgery patients

Patient	Gender	Age (year)	Age of seizure onset	Epilepsy duration	Seizure frequency	Drugs	Psychiatric disorders
Tissue source: Amygdala							
1	Female	49	3 years after birth	46	weekly	Levetiracetam Carbamazepine	Mild depression
2	Male	26	2 days after birth	26	Monthly	Levetiracetam Topiramate Lacosamide	Cognitive Impairment
Tissue source: Hippocampus							
3	Female	34	10 months after birth	33	Weekly	Levetiracetam Carbamazepine Lacosamide	Depression
4	Male	26	2 days after birth	26	Monthly	Levetiracetam Topiramate Lacosamide	Cognitive Impairment
Tissue source: Neocortex							
5	Male	39	30 years after birth	9	Monthly	Levetiracetam Lacosamide	-
6	Female	44	5 years after birth	39	Weekly	Carbamazepine Phenobarbital	-

7	Male	26	5 years after birth	21	Daily	Levetiracetam Phenobarbital Lacosamide	-
---	------	----	---------------------	----	-------	--	---

Accepted Manuscript (Uncorrected Proof)




Fig. 1: Primary cultures of astrocytes derived from patients with intractable epilepsy derived from the amygdala, neocortex, and hippocampus.

Accepted Manuscript (Uncorrected Proof)




Fig. 2: Expression of vimentin and fibronectin in astrocytes derived from human epileptic brain tissues. Cells stained for markers are green, and nuclei stained with propidium iodide (PI) are red.




Fig. 3: Treatment of different SMs on astrocyte cell survival. Astrocyte cells were treated with different SMs, and cell viability was measured 48 and 72 hours after treatment (N in each group =4). * and **** indicate $P < 0.05$ and $P < 0.0001$, respectively.